category:news Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s. After the fights between GLP1 produces (Eli Lilly, Novo Nordisk) and compounders, the dust is mostly settled. Most compounders have stopped creating compounded GLP1s (a few still persist) and the supply shortages that enabled 503A/503B production of GLP1s has ended. There's another turn in the story – now a firm out of Houston Texas has f...